News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Opinion|Videos|October 11, 2024

Meningococcal Infection and NMOSD

Author(s)Sean Pittock, MD

Key Takeaways

Eculizumab and ravulizumab increase meningococcal infection risk, necessitating vaccination in treated patients.
Phase 3 and long-term studies emphasize the need for vigilant monitoring and prophylactic measures despite vaccination.
Breakthrough infections can occur even with vaccination, highlighting the need for ongoing risk assessment.
The impact of meningococcal vaccination on disease relapse activity requires further investigation.

SHOW MORE

Sean Pittock, MD, discusses the risks of meningococcal infection associated with eculizumab and ravulizumab in phase 3 and long-term extension studies, as well as his interpretation of the concerns surrounding meningococcal vaccination and its potential impact on relapse activity.

Episodes in this series

EP. 1 Relapses and Disability Accumulation in NMOSD

EP. 1 Relapses and Disability Accumulation in NMOSD

EP. 2 Treatments With Higher Efficacy and Relapses in NMOSD

EP. 2 Treatments With Higher Efficacy and Relapses in NMOSD

EP. 3 Ravulizumab Long-Term Data and Management of NMOSD

EP. 3 Ravulizumab Long-Term Data and Management of NMOSD

EP. 4 The Evolving Understanding of NMOSD Pathophysiology and the Role of Complement System

EP. 4 The Evolving Understanding of NMOSD Pathophysiology and the Role of Complement System

EP. 5 Treatment Options to Manage and Prevent Relapses in NMOSD

EP. 5 Treatment Options to Manage and Prevent Relapses in NMOSD

EP. 6 Importance of Diverse Mechanisms of Action to Effectively Treat NMOSD

EP. 6 Importance of Diverse Mechanisms of Action to Effectively Treat NMOSD

EP. 7 Complement Inhibitors in NMOSD

EP. 7 Complement Inhibitors in NMOSD

EP. 8 Meningococcal Infection and NMOSD

EP. 8 Meningococcal Infection and NMOSD

EP. 9 Long-term NMOSD Data

EP. 9 Long-term NMOSD Data

EP. 10 Use of Long-term NMOSD Data in Clinical Practice

EP. 10 Use of Long-term NMOSD Data in Clinical Practice

Video content above is prompted by the following:

Discuss the risk of meningococcal infection with eculizumab and ravulizumab in phase 3 and long-term extension studies.
There may be concerns with meningococcal vaccination and its impact on relapse activity. What is your interpretation of these data?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Latest CME

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA, FASCO; Girish Dhall, MD

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Abigail Schwaede, MD; Alexis Lizarraga, MD, MS

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline

Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial

Sanofi's Oral TREM2 Agonist SAR448851 Advances to Phase 2 TREMHANCE Trial in Early Alzheimer Disease

Building the Foundation for Earlier Alzheimer Disease Diagnosis

FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date